newsfilter
← Latest News
GlobeNewswire·

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced a recent publication in the Journal of Cancer Research